OverviewSuggest Edit

Accelerate Diagnostics is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

TypePublic
Founded2004
HQTucson, US
Websiteacceleratediagnostics.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2018)287(+21%)
Job Openings24
Revenue (FY, 2018)$5.7 M(+36%)
Share Price (Oct 2019)$17.2 (-4%)

Key People/Management at Accelerate Diagnostics

Lawrence Mehren

Lawrence Mehren

President, Chief Executive Officer & Director
Steve Reichling

Steve Reichling

CFO
Kurt Reinhardt

Kurt Reinhardt

Head of Operations
Steve Metzger

Steve Metzger

Head of Discovery
Andrew Ghusson

Andrew Ghusson

Head of Product Development
Pete Bantock

Pete Bantock

Head of Clinical Intervention Solutions
Show more

Accelerate Diagnostics Office Locations

Accelerate Diagnostics has offices in Tucson and Castelldefels
Tucson, US (HQ)
3950 S Country Club Rd
Castelldefels, ES
1 Carrer Esteve Terradas
Show all (2)

Accelerate Diagnostics Financials and Metrics

Accelerate Diagnostics Revenue

Accelerate Diagnostics's revenue was reported to be $5.67 m in FY, 2018
USD

Revenue (Q1, 2019)

1.8m

Gross profit (Q1, 2019)

834.0k

Gross profit margin (Q1, 2019), %

47.7%

Net income (Q1, 2019)

(21.7m)

EBIT (Q1, 2019)

(18.8m)

Market capitalization (16-Oct-2019)

937.1m

Closing stock price (16-Oct-2019)

17.2

Cash (31-Mar-2019)

75.3m
Accelerate Diagnostics's current market capitalization is $937.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

48.3k122.0k147.0k246.0k4.2m5.7m

Revenue growth, %

153%20%67%

Cost of goods sold

1.0m3.2m

Gross profit

3.2m2.5m
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

12.8k13.0k14.0k92.0k163.0k24.0k699.0k828.0k801.0k1.7m1.4m1.8m

Cost of goods sold

135.0k191.0k492.0k717.0k680.0k916.0k

Gross profit

564.0k637.0k309.0k975.0k675.0k834.0k

Gross profit Margin, %

81%77%39%58%50%48%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

30.0m53.6m120.6m19.2m28.5m66.3m

Accounts Receivable

24.4k78.0k77.0k155.7m

Inventories

8.1m7.7m

Current Assets

42.1m67.1m134.2m78.4m120.5m177.6m
Quarterly
USDQ3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

33.5m65.2m57.9m47.4m35.2k25.2m72.0m37.5m28.7m9.9m62.6m34.4m126.8m66.8m61.6m75.3m

Inventories

4.4m5.7m7.3m10.1m11.3m9.4m8.6m

Current Assets

44.6m79.7m72.7m59.7m49.4k40.9m120.3m105.4m91.7m70.3m143.3m131.3m207.1m212.6m192.9m164.0m

PP&E

1.0m1.9m2.3m3.5m3.8k3.7m5.2m5.0m4.8m3.9m4.8m4.7m5.9m5.4m7.4m7.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(15.3m)(3.4m)(45.5m)(66.4m)(64.0m)(88.3m)

Depreciation and Amortization

362.5k43.0k1.8m2.4m2.2m2.6m

Inventories

10.3k10.0k(7.8m)(4.2m)

Accounts Payable

204.2k236.0k329.0k(1.2m)1.1m(748.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(13.4m)(22.2m)(8.9m)(21.1m)(32.3m)(15.1m)(50.2m)(14.2m)(30.7m)(47.7m)(20.8m)(44.0m)(66.1m)(21.7m)

Depreciation and Amortization

323.0k592.0k326.0k5.0k1.2m545.0k1.8m3.0k1.1m1.6m544.0k1.1m1.7m

Inventories

4.4m(5.5m)(7.1m)(1.9m)(4.3m)(5.2m)(1.6m)

Accounts Payable

6.8k718.0k496.0k528.0k2.4m1.7k(329.0k)494.0k1.8m103.0k1.3m528.0k359.0k701.0k206.0k(524.0k)1.2m
USDY, 2019

Financial Leverage

4 x
Show all financial metrics

Accelerate Diagnostics Online and Social Media Presence

Embed Graph

Accelerate Diagnostics News and Updates

Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

TUCSON, Ariz., Sept. 18, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. "We are thrilled with the results of these clinical...

Accelerate Diagnostics to Present at the William Blair Growth Stock Conference on June 6, 2019

TUCSON, Ariz., May 24, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Chief Executive Officer, Larry Mehren, and Chief Financial Officer, Steve Reichling will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019...

Accelerate Diagnostics Schedules Call to Review First Quarter 2019 Results

TUCSON, Ariz., April 26, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that it will report financial results for the first quarter of 2019 after the market close on Thursday, May 9, 2019. The Company's management will host a conference call at 4:30 p.m....

Accelerate Diagnostics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019

TUCSON, Ariz., March 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present at the Cowen and Company 39th Annual Health Care Conference in Boston on Wednesday, March 13, 2019 at 8:40 AM Eastern Time. Investors may...

Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results

TUCSON, Ariz., Jan. 6, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S. instruments placed under commercial contract during the fourth...

Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results

TUCSON, Ariz., Jan. 6, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S. instruments placed under commercial contract during the fourth...
Show more

Accelerate Diagnostics Frequently Asked Questions

  • When was Accelerate Diagnostics founded?

    Accelerate Diagnostics was founded in 2004.

  • Who are Accelerate Diagnostics key executives?

    Accelerate Diagnostics's key executives are Lawrence Mehren, Steve Reichling and Kurt Reinhardt.

  • How many employees does Accelerate Diagnostics have?

    Accelerate Diagnostics has 287 employees.

  • What is Accelerate Diagnostics revenue?

    Latest Accelerate Diagnostics annual revenue is $5.7 m.

  • What is Accelerate Diagnostics revenue per employee?

    Latest Accelerate Diagnostics revenue per employee is $19.8 k.

  • Who are Accelerate Diagnostics competitors?

    Competitors of Accelerate Diagnostics include DotLab, Aquaro Histology and Cambridge Epigenetix.

  • Where is Accelerate Diagnostics headquarters?

    Accelerate Diagnostics headquarters is located at 3950 S Country Club Rd, Tucson.

  • Where are Accelerate Diagnostics offices?

    Accelerate Diagnostics has offices in Tucson and Castelldefels.

  • How many offices does Accelerate Diagnostics have?

    Accelerate Diagnostics has 2 offices.